Amprius Technologies Q3 Earnings Call Highlights

Amprius reported a Q3 net loss of $3.5M, with adjusted EBITDA at -$1M. The company maintained its full-year gross margin forecast of 28% and expects Q4 sales of $43.3M. Amprius is expanding manufacturing to meet demand, with a $75M contract for a U.S. battery production line. It also introduced new products for aviation and deep-sea applications, ending Q3 with $60.7M in cash.

Original reporting
Published Nov 11, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amprius Technologies Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$AMPXBullishMed
01

Why it matters

The Q3 earnings release provides fresh guidance, margin outlook, and a major defense contract, offering new material information for traders.

02

Market read

First‑report earnings and contract news could drive short‑term price movement for AMPX.

03

What to watch

Cash balance of $60.7M may constrain near‑term growth; reliance on defense contracts adds concentration risk.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Amprius Technologies (NYSE:AMPX) develops silicon‑anode lithium‑ion batteries for aviation, drones, and defense applications.

Company-level read

Ticker impact

$AMPXBullishHigh confidence
Context

Q3 earnings disclosed a net loss of $3.5M, maintained 28% gross margin guidance and announced a $75M defense contract and a $100M conversion project.

Expected impact

potential upside as investors price in higher margins and the sizable defense contract

Evidence & confidence

Guidance lift and $75M contract are fresh, material disclosures for a micro‑cap battery maker.

Market effects

May boost sentiment for niche battery and defense‑tech stocks.

Highlights U.S. defense spending pipeline, modest effect on broader market.

Limited to investors tracking battery technology and defense contracts.

Counterpoint

The company remains loss‑making with limited cash; execution risk on the $100M conversion could weigh on price.

Key entities

  • Amprius Technologies

    Battery manufacturer listed on NYSE.

  • U.S. Department of War

    Awarded a $75M contract to Amprius.

Related articles

$AMPXMedAI 8/10

Amprius (AMPX) Q3 2026 Earnings Call Transcript

Amprius reported Q3 2026 revenue of $39.1M, up 83% YoY, raising its full-year target to $145M. The company introduced SiCore 500 cells for aviation and secured a $75M U.S. defense contract. Amprius expanded into maritime vehicles and partnered with U.S. manufacturers for NDAA-compliant production.

$AMPXHigh

Amprius Technologies falls 7% on third quarter earnings miss

Amprius Technologies (NYSE:AMPX) reported Q3 earnings missing estimates with a loss of $0.02 per share, though revenue of $39.1M beat expectations. Shares fell 7.7% after-hours. The company raised its full-year 2026 revenue outlook to $145M, above analyst forecasts. Gross profit rose 217% YoY to $10.5M, with gross margin improving to 27%. Amprius secured a $75M U.S. Department of War contract and introduced a new battery cell.

$AMPXMed

Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent

Amprius Technologies, Inc. (AMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amprius Technologies Reports Third Quarter 2026 Financial Results and Recent Business Highlights • Q3 2026 revenue increased 83% year-over-year to $39.1 million • Net loss of $3.5 million, a 10% year-over-year improvement • Increasing 2026 revenue outlook to $145 mil

$AMPXHigh

AMPX Stock Jumps As Defense Deals Supercharge Growth Story

Amprius Technologies Inc. (NYSE: AMPX) shares rose 8.38% on October 21, 2026, driven by U.S. Department of War funding and a partnership with Caminus for battery production. The company secured $75M in funding for a high-energy-density cell plant, with revenue growth but negative margins. Canaccord Genuity initiated coverage with a Buy rating and $14 price target.